Eighteen states have adopted Limited Access Marijuana Product Laws permitting only low (or zero) Tetrahydrocannabinol (THC) and high Cannabidiol (CBD) products to treat several, often specified conditions, usually uncontrolled epilepsy disorders. THC is the psychoactive substance in marijuana that alters users’ senses and cause mood changes, and can lead to changes in behavior. Cannabidiol, however, has mild psychoactive effects. This resource, developed by the Network for Public Health Law and released on July 19, 2017, provides a brief overview of jurisdictions with statutory and regulatory provisions legalizing limited access medical marijuana programs. The survey complements the network's other survey results on Medical Marijuana Programs.
For more information about the document, go to https://www.networkforphl.org/resources_collection/2017/07/19/911/survey_limited_access_to_medical_marijuana_laws/?utm_source=Network+Report+7-20-17&utm_campaign=Network+Report+7-20-17&utm_medium=email&utm_content=312.